Cytokine profiles in acute liver injury—Results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group

Changes in levels of cytokines and chemokines have been proposed as possible biomarkers of tissue injury, including liver injury due to drugs. Recently, in acute drug-induced liver injury (DILI), we showed that 19 of 27 immune analytes were differentially expressed and that disparate patterns of imm...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 13; no. 10; p. e0206389
Main Authors Bonkovsky, Herbert L., Barnhart, Huiman X., Foureau, David M., Steuerwald, Nury, Lee, William M., Gu, Jiezhun, Fontana, Robert J., Hayashi, Paul J., Chalasani, Naga, Navarro, Victor M., Odin, Joseph, Stolz, Andrew, Watkins, Paul B., Serrano, Jose
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 25.10.2018
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Changes in levels of cytokines and chemokines have been proposed as possible biomarkers of tissue injury, including liver injury due to drugs. Recently, in acute drug-induced liver injury (DILI), we showed that 19 of 27 immune analytes were differentially expressed and that disparate patterns of immune responses were evident. Lower values of serum albumin (< 2.8 g/dL) and lower levels of only four analytes, namely, IL-9, IL-17, PDGF-bb, and RANTES, were highly predictive of early death [accuracy = 96%]. The goals of this study were to assess levels of the same 27 immune analytes in larger numbers of subjects to learn whether the earlier findings would be confirmed in new and larger cohorts of subjects, compared with a new cohort of healthy controls. We studied 127 subjects with acute DILI enrolled into the US DILIN. We also studied 118 subjects with severe acute liver injury of diverse etiologies, enrolled into the ALF SG registry of subjects. Controls comprised 63 de-identified subjects with no history of liver disease and normal liver tests. Analytes associated with poor outcomes [death before 6 months, n = 32 of the total of 232 non-acetaminophen (Apap) subjects], were lower serum albumin [2.6 vs 3.0 g/dL] and RANTES [6,458 vs 8,999 pg/mL] but higher levels of IL-6 [41 vs 18], IL-8 [78 vs 48], and MELD scores [30 vs 24]. Similar patterns were observed for outcome of death/liver transplant within 6 months. A model that included only serum albumin < 2.8 g/dL and RANTES below its median value of 11,349 had 83% (or 81%) accuracy for predicting early death (or early death/liver transplant) in 127 subjects from DILIN. No patterns of serum immune analytes were reflective of the etiologies of acute liver failure, but there were cytokine patterns that predicted prognosis in both acute DILI and ALF.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Members of the Research Consortia are provided in Supporting Information.
Competing Interests: Within the past three years Dr. Bonkovsky has served as a consultant to Alnylam, Inc, Blue Pharma, Clinuvel, Inc, Mitsubishi-Tanabe, Recordati Rare Chemicals, and Stoke Pharma; he has received research support from Alnylam and Gilead Sciences, Inc; none of these is related to this paper. Dr. Lee serves as consultant to Lilly, Novartis and Repros and receives research support for non-DILI studies from Gilead, Merck, Ocera, Cumberland, and Conatus; none of these is related to this paper. Dr. Fontana has received research support from Gilead, Bristol-Myers Squibb and Janssen; none of these is related to this paper. Dr. Chalasani has consulting agreements with several pharmaceutical companies none of which is relevant to this paper. Dr. Odin has served as a consultant to Intercept Pharmaceuticals and has received research support from Zydus Pharma., Cymabay Therapeutics, and Taiwanj Pharma; none of these is related to this paper. Dr. Watkins has consulting agreements with several pharmaceutical companies none of which is relevant to this paper. Drs. Barnhart, Foureau, Gu, Hayashi, Navarro, Serrano, and Steuerwald report no conflicts of interest. All authors also affirm that none of their disclosures alters their adherence to all PLOS ONE policies on sharing data and materials, as detailed in the PLOS ONE guide for authors [http://journals.plos.org/ploosone/s/competing-interests].
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0206389